TE
科技回声
首页24小时热榜最新最佳问答展示工作
GitHubTwitter
首页

科技回声

基于 Next.js 构建的科技新闻平台,提供全球科技新闻和讨论内容。

GitHubTwitter

首页

首页最新最佳问答展示工作

资源链接

HackerNews API原版 HackerNewsNext.js

© 2025 科技回声. 版权所有。

Covid-19 vaccines: In the rush for regulatory approval, do we need more data?

2 点作者 AndrewBissell大约 4 年前

2 条评论

brobdingnagians大约 4 年前
&gt; But what’s the rush, asks Peter Doshi, and is just six months of data from now unblinded trials acceptable?<p>&gt; Unblinded and without a control group—what about safety?<p>There shouldn&#x27;t be a rush. Now that such a large number of people who wanted it has gotten it, we might as well do the full 10-years-plus process of seeing all the effects and going through the normal process. It shouldn&#x27;t be used as a reason to say &quot;no more studies needed, since it got approval&quot;, or &quot;emergency authorisation seems to have worked, so let&#x27;s just skip to full approval&quot;.
评论 #27265254 未加载
kmos17大约 4 年前
Hmm, I would say 600k deaths in the US alone qualifies as a rush when the vaccines are reducing these to 0. There is in fact quite a lot of data out there.